DHR vs INTC: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Intel Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
Danaher Corporation · Healthcare
$174.04
+13.2% upside to fair value
Grade B
VS
Intel Corporation · Technology
$82.54
-5.4% upside to fair value
Grade D
QuantHub Verdict
DHR has more upside to fair value
(+13.2%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
INTC |
| Current Price |
$174.04 |
$82.54 |
| Fair Value Estimate |
$197.01 |
$78.12 |
| Upside to Fair Value |
+13.2%
|
-5.4%
|
| Market Cap |
$123.2B |
$414.4B |
| Forward P/E |
33.4x
|
-132.2x
|
| EV / EBITDA |
20.3x
|
50.1x
|
| Price / Sales |
5.0x
|
7.7x
|
| Price / FCF |
23.3x
|
-132.9x
|
| Revenue Growth YoY |
+3.7%
|
+7.2%
|
| Gross Margin |
60.7%
|
35.4%
|
| Operating Margin |
21.0%
|
-9.4%
|
| Return on Equity |
7.1%
|
-3.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.3%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation is a diversified healthcare company focused on medical diagnostics, life sciences, and biotechnology, generating approximately $24 billion in revenue with a strong recurring revenue base of over 81%. The company benefits from a high gross margin of 60.7% and solid operating margin of 21%, supported by a seasoned management team with a proven capital allocation track record inc…
Intel Corporation is a leading semiconductor company transitioning to a foundry business model while maintaining significant revenue from client computing and data center segments. Despite a strong market position and experienced leadership, the company faces earnings pressure with a 354% decline in earnings in the most recent quarter and negative margins. The stock trades at $82.54, which is 5.4…
Accumulation Zones
| Metric |
DHR |
INTC |
| Zone Low |
$147.76 |
$58.59 |
| Zone High |
$167.46 |
$66.40 |
| In Buy Zone? |
No
|
No
|